[1] Shaw J E, Sicree R A, Zimmet P Z. Global estimates of the prevalence ofdiabetes for 2010 and 2030[J]. Diabetes Research & Clinical Practice, 2010, 87(1):4-14.
[2] Xu Y1, Wang L, He J,Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G. Prevalence and control of diabetes in Chinese adults. JAMA, 2013,310(9):948-959.
[3] Wang T, Xu Y, Xu M, et al. Awareness, treatment and control of cardiometabolic disorders in Chinese adults with diabetes: a national representative population study[J]. Cardiovascular Diabetology, 2015, 14(1):28.
[4] Satchell S C, Braet F. Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier[J]. American Journal of Physiology - Renal Physiology, 2009, 296(5):F947-F956.
[5] Salmon A H, Ferguson J K, Burford J L, et al. Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction[J]. Journal of the American Society of Nephrology Jasn, 2012, 23(8):1339.
[6] Richard A. Lafayette, Maurice Druzin, Richard Sibley, et al. Nature of glomerular dysfunction in pre-eclampsia 1[J]. Kidney International, 1998, 54(4):1240-1249.
[7] Fridén V, Oveland E, Tenstad O, et al. The glomerular endothelial cell coat is essential for glomerular filtration[J]. Kidney International, 2011, 79(12):1322-30.
[8] Sung S H, Ziyadeh F N, Wang A, et al. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice[J]. Journal of the American Society of Nephrology, 2006, 17(11):3093-3104.
[9] A. Kuwabara, M. Satoh, N. Tomita, et al. Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty rats[J]. Diabetologia, 2010, 53(9):2056-2065.
[10] HansPeter Hammes, Yuxi Feng, Frederick Pfister, et al. Diabetic Retinopathy: Targeting Vasoregression[J]. Diabetes, 2011, 60(1):9-16.
[11] M Mizutani, T S Kern, M Lorenzi. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy.[J]. Journal of Clinical Investigation, 1996, 97(12):2883-90.
[12] Park D Y, Lee J, Kim J, et al. Plastic roles of pericytes in the blood–retinal barrier[J]. Nature Communications, 2017, 8:15296.
[13] Ia V D O, Raterman H G, Nurmohamed M T, et al. Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus.[J]. Mediators of Inflammation,2010,(2010-05-03), 2010, 2010(1):792393.
[14] Maric-Bilkan C, Flynn E R, Chade A R. Microvascular disease precedes the decline in renal function in the streptozotocin-induced diabetic rat[J]. American Journal of Physiology Renal Physiology, 2012, 302(3):F308.
[15] Lindenmeyer M T, Kretzler M, Boucherot A, et al. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy[J]. Journal of the American Society of Nephrology Jasn, 2007, 18(6):1765.
[16] Sivaskandarajah G A, Jeansson M, Maezawa Y, et al. Vegfa Protects the Glomerular Microvasculature in Diabetes[J]. Diabetes, 2012, 61(11):2958-2966.
[17] Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. [J]. Nature Medicine, 2007, 13(11):1349-1358.
[18] Weil EJ, Lemley KV, Mason CC, Yee B, Jones LI, Blouch K, LovatoT, Richardson M, Myers BD, Nelson RG. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int 82: 1010–1017, 2012.
[19] Kameda Y, Babazono T, Uchigata Y, et al. Renal function after intravitreal administration of vascular endothelial growth factor inhibitors in patients with diabetes and chronic kidney disease:[J]. Journal of Diabetes Investigation, 2018, 9(4):937-939.
[20] Erturk I, Yesildal F, Acar R, et al. Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease:Associations with laboratory findings, comorbidities, and medications[J]. Saudi Medical Journal, 2018, 39(6):586-591.
[21] Suzuki Y, Montagne K, Nishihara A, et al. BMPs Promote Proliferation and Migration of Endothelial Cells via Stimulation of VEGF-A/VEGFR2 and Angiopoietin-1/Tie2 Signalling[J]. Journal of Biochemistry, 2008, 143(2):199-206.
[22] Gnudi L. Angiopoietins and diabetic nephropathy[J]. Diabetologia, 2016, 59(8):1616-1620.
[23] Dessaptbaradez C, Woolf A S, White K E, et al. Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease.[J]. Journal of the American Society of Nephrology Jasn, 2014, 25(1):33.
[24] Rizkalla B, Forbes J M, Cao Z, et al. Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system.[J]. Journal of Hypertension, 2005, 23(1):153-64.
[25] Marie Jeansson, Alexander Gawlik, Gregory Anderson, et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest[J]. Journal of Clinical Investigation, 2011, 121(6):2278-2289.
[26] Mikhail M, Vachon PH, D'OrleansJuste P, et al. ROLE OF ENDOTHELIN-1 AND ITS RECEPTORS ETA AND ETB IN THE SURVIVAL OF HUMAN VASCULAR ENDOTHELIAL CELLS.[J]. Canadian Journal of Physiology and Pharmacology, 2017, 95(10).
[27] Zhong F, Chen H, Wei C, et al. Reduced Kruppel-like factor 2 expression may aggravate the endothelial injury of diabetic nephropathy[J]. Kidney International, 2015, 87(2):382-395.
[28] Zhang X, Sun D, Song J W, et al. Endothelial cell dysfunction and glycocalyx – A vicious circle[J]. Matrix Biology, 2018.
[29] Sieve I, Munster-Kuhnel A, Hilfiker-Kleiner D. Regulation and function of endothelial glycocalyx layer in vascular diseases[J]. Vascular Pharmacology, 2017, 100.
[30] Salmon A H, Satchell S C. Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability[J]. Journal of Pathology, 2012, 226(4):562-574.
[31] Floege J, Eitner F, Alpers C E. A New Look at Platelet-Derived Growth Factor in Renal Disease[J]. Journal of the American Society of Nephrology, 2008, 19(1):12-23.
[32] Lindahl P, Hellström M, Kalén M, et al. Paracrine PDGF-B/PDGF-Rbeta signaling controls mesangial cell development in kidney glomeruli.[J]. Development, 1998, 125(17):3313.
[33] Bjarnegård M, Enge M, Norlin J, et al.Endothelium-specific ablation of PDGFB leads to pericyte loss and glomerular, cardiac and placental abnormalities.[J]. Development, 2004, 131(8):1847-1857.
[34] Figueira M F, Monnerat‐Cahli G, Medei E, et al. MicroRNAs: potential therapeutic targets in diabetic complications of the cardiovascular and renal systems[J]. Acta Physiologica, 2014, 211(3):491-500.
[35] Mu J, Pang Q, Guo Y H, et al. Functional implications of microRNA-215 in TGF-β1-induced phenotypic transition of mesangial cells by targeting CTNNBIP1.[J]. Plos One, 2013, 8(3):e58622.[58]